Meeting Report

Immune Checkpoint Inhibitor–Based Therapy as a Backbone in Cancer Treatment

Presented by Krista M. Rubin,(1) MS, FNP-BC, and Anthony J. Olszanski,(2) MD, RPh

From (1)Massachusetts General Hospital Cancer Center, Boston, Massachusetts; (2)Fox Chase Cancer Center of Temple Health, Philadelphia, Pennsylvania

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2020;11(3):231–233 | https://doi.org/10.6004/jadpro.2020.11.3.3 | © 2020 Harborside™


  

ABSTRACT

At JADPRO Live 2019, Krista M. Rubin, MS, FNP-BC, and Anthony J. Olszanski, MD, RPh, reviewed the basic concepts of immunotherapy and the current treatment landscape, and discussed emerging data for immune checkpoint inhibitor–based combinations that are being explored in late-stage clinical trials. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.